For cancer vaccines to eliminate tumor cells from the patient’s body, there has to be a debulking, or reduction in the tumor burden. This is critical because many advanced cancer patients have more tumor cells than the killer cells can handle by themselves. The normal ways of reducing the burden are surgery, chemotherapy, and radiation. Unfortunately, these are all immunosuppressive, putting the killer cells at a disadvantage. Chemotherapy drugs mostly affect cells that reproduce rapidly by interfering with their DNA. Likewise, radiation causes breaks in DNA that trigger self-destruct when that cell tries to divide. These methods can be compared to trying to win a battle by bombing not just he enemy, but your own troops as well.
Hyperthermia, on the other hand, is an ideal debulking step because it increases killer cell efficiency. After all, the fever accompanying an infection is your body’s way of slowing the germ’s reproduction and increasing the speed and efficiency of the immune system cells. Hyperthermia and vaccine-primed killer cells make an ideal “one-two” punch for attacking cancer. The fever not only kills the tumor cells by shutting off their blood flow, it revs up the killer cells to their maximum potential.
Thursday, April 9, 2009
Sunday, April 5, 2009
How Vaccines work for Cancer
Most vaccines are for prevention, not for treating established disease. It is fairly easy to stimulate antibodies and other specific immunity against a foreign germ which may attack in the future. Cancer, however, involves “self” cells which have turned rogue, and the immune system has instructions to leave “self” cells alone. Without this protection, autoimmune diseases would be much more common. So, how do we stimulate the immune system to attack tumor cells?
One way is to remove tumor cells, kill them with radiation, and mix them with immune-stimulant chemicals. This mixture is then injected back into the body in the hopes that it will now be seen as foreign. As expected, this approach is complex, costly, and has limited effectiveness. Several other vaccine strategies have been tried, but Dendritic Cells (DC), hold tremendous potential as they can directly stimulate killer T cells without any assistance. We can grow millions of DC from a unit of whole blood, and each DC can activate up to 3,000 killer cells. Most tumor immunologists agree that a ratio of killer cells to tumor cells of at least 10: 1 is required for a complete response to vaccine treatment. To accomplish this, we must first remove at least half of the cancer cells in the body prior to the vaccine treatment. Unfortunately, radiation, surgery, and chemotherapy all degrade the killer cells, so another method must be used.
One way is to remove tumor cells, kill them with radiation, and mix them with immune-stimulant chemicals. This mixture is then injected back into the body in the hopes that it will now be seen as foreign. As expected, this approach is complex, costly, and has limited effectiveness. Several other vaccine strategies have been tried, but Dendritic Cells (DC), hold tremendous potential as they can directly stimulate killer T cells without any assistance. We can grow millions of DC from a unit of whole blood, and each DC can activate up to 3,000 killer cells. Most tumor immunologists agree that a ratio of killer cells to tumor cells of at least 10: 1 is required for a complete response to vaccine treatment. To accomplish this, we must first remove at least half of the cancer cells in the body prior to the vaccine treatment. Unfortunately, radiation, surgery, and chemotherapy all degrade the killer cells, so another method must be used.
Saturday, April 4, 2009
High Fever & Cancer
Most cases of spontaneous regression of cancer (when it disappears without treatment), have occurred after a fever in excess of 104 F. There is a range between 103.5 and 106 degrees F where tumor cells will die but normal tissue will survive. It’s not the heat that kills, it’s the difference in blood supply and metabolism, or how the two types of cells get energy from food and oxygen. Normal cells are organized with precise borders, like a neat suburban tract seen from the air. Power, gas, and clean water flow in, sewage flows out, and the systems work well because they are designed for the number of housing units.
Now look at a shantytown slum where the shacks are piled on top of each other, with a muddy ditch for water supply and sewage disposal. That’s a tumor colony, and because they don’t belong there, never signed a lease with management, and violate the zoning laws, the cells are always running a deficit for energy. Your cells have two ways to get the energy dollars called ATP to spend: clean and slow with oxygen, quick and dirty without it, resulting in lactic acid, which causes muscle soreness after hard exercise.
The rapid growth and poor supply of tumor cells means that their lactic acid buildup is higher, and the pH inside the cells is lower than normal cells
At high fevers, the part of the brain that regulates temperature called the hypothalamus shuts down nonessential supply girds to conserve oxygen to the brain, which cannot make lactic acid. Cancer cells are forced to choose: starve for energy and die, or make more lactic acid, which they cannot flush away, and they die from acid buildup. A hundred years ago a doctor in Baltimore named William Coley saw that cancer patients who had high fevers after surgery did better than those who did not. He used bacterial toxins to induce high fevers, and achieved a remarkable response rate: up to 45% of bone and breast cancer patients. This is superior to many chemotherapy drugs, but after the antibiotic revolution, his therapy faded into obscurity, although his toxins are still legally available through a clinic in Wisconsin.
Now look at a shantytown slum where the shacks are piled on top of each other, with a muddy ditch for water supply and sewage disposal. That’s a tumor colony, and because they don’t belong there, never signed a lease with management, and violate the zoning laws, the cells are always running a deficit for energy. Your cells have two ways to get the energy dollars called ATP to spend: clean and slow with oxygen, quick and dirty without it, resulting in lactic acid, which causes muscle soreness after hard exercise.
The rapid growth and poor supply of tumor cells means that their lactic acid buildup is higher, and the pH inside the cells is lower than normal cells
At high fevers, the part of the brain that regulates temperature called the hypothalamus shuts down nonessential supply girds to conserve oxygen to the brain, which cannot make lactic acid. Cancer cells are forced to choose: starve for energy and die, or make more lactic acid, which they cannot flush away, and they die from acid buildup. A hundred years ago a doctor in Baltimore named William Coley saw that cancer patients who had high fevers after surgery did better than those who did not. He used bacterial toxins to induce high fevers, and achieved a remarkable response rate: up to 45% of bone and breast cancer patients. This is superior to many chemotherapy drugs, but after the antibiotic revolution, his therapy faded into obscurity, although his toxins are still legally available through a clinic in Wisconsin.
Sunday, March 29, 2009
The Current Types of Cancer Vaccines
There are two types of vaccines: preventative and therapeutic. Most vaccines we receive during childhood are for prevention, they stimulate the immune system to make antibodies and killer cells that remember the germ’s protein ID coating. Cancer vaccines are therapeutic, designed to be given after the person becomes sick with the disease. They often don’t work well because prevention is easier than treatment, and your immune system reacts differently towards “self” than to foreign bacteria and viruses, “non-self”.
Cancer cells come from your own cells that have lost their ability to control their growth. The immune system often doesn’t see the tumor cells as dangerous, just self cells. After all, when the immune system starts attacking the body, we call it autoimmunity. So, in a sense, cancer vaccines try to teach the immune system that something it sees as harmless is really a threat.
Some cancer vaccines try to stimulate antibodies, but these are small proteins that are usually inadequate to kill a tumor cell. Most vaccines try to stimulate killer cells to attack and destroy tumor cells the same way they would kill a cell infected by a virus. This can be done in several ways: by injecting the patient with their own cancer cells, killed by radiation and mixed with immune-stimulating chemicals, by injection with protein pieces of the tumor cell (peptides), and with Dendritic Cells (DC). DC vaccines are superior in many ways in that the can stimulate killer cells directly, instead of relying on other cells to help out.
Cancer cells come from your own cells that have lost their ability to control their growth. The immune system often doesn’t see the tumor cells as dangerous, just self cells. After all, when the immune system starts attacking the body, we call it autoimmunity. So, in a sense, cancer vaccines try to teach the immune system that something it sees as harmless is really a threat.
Some cancer vaccines try to stimulate antibodies, but these are small proteins that are usually inadequate to kill a tumor cell. Most vaccines try to stimulate killer cells to attack and destroy tumor cells the same way they would kill a cell infected by a virus. This can be done in several ways: by injecting the patient with their own cancer cells, killed by radiation and mixed with immune-stimulating chemicals, by injection with protein pieces of the tumor cell (peptides), and with Dendritic Cells (DC). DC vaccines are superior in many ways in that the can stimulate killer cells directly, instead of relying on other cells to help out.
Saturday, March 28, 2009
Melanoma Vaccines I
Because of the toxicity of chemotherapy and radiation, doctors have tried to harness the power of the immune system to fight cancer. The immune system has many specialized units, but it is the killer cells, or Cytotoxic T Lymphocytes (CTL), that are most important in cancer immunotherapy. These white blood cells “feel” other cells to find a protein called the HLA complex on the cell surface. This serves as an ID, so transplanted organs are matched to similar HLA types. The HLA complex also carries samples of the proteins made in the cell. This is important because viruses hijack cells and force them to make viral parts, which are packaged into HLA and shown to the killer cell Health Inspector, which destroys the cell.
The killer cells get their information from cells called Dendritics, (DC), which act as scouts for the immune system. They take up bits of germs and show them to the killer cells for targeting purposes. The DC can be cultured from whole blood, so DC vaccines allow us to program the immune system like a computer. This has tremendous potential for the field of cancer vaccines.
The killer cells get their information from cells called Dendritics, (DC), which act as scouts for the immune system. They take up bits of germs and show them to the killer cells for targeting purposes. The DC can be cultured from whole blood, so DC vaccines allow us to program the immune system like a computer. This has tremendous potential for the field of cancer vaccines.
“One Size Fits All” Cancer Drugs
For a drug candidate to receive serious consideration for drug company funding, it has to fit a certain business model. Currently, the preferred model is a pill or liquid that can be injected into the patient. These drugs tend to have a single pathway of action against the cancer cell. Mutations in the tumor cell can quickly render the drug useless. If this is the case, why do companies continue down this road to failure? Basically, these business models are the only ones they know. These types of drugs fit into an established system of production, shipping, storage, administration, and billing. This model works well for simple diseases, but cancer is unique in that no two patients with the same type of cancer are alike. We can even demonstrate that in a melanoma patient, the tumors on their legs are genetically different than the ones on their back. It’s like having 100 different kinds of crabgrass weed growing on your lawn. By the time you have tried five different weed killers, you lawn is dead from the accumulated toxins.
The Business Model of Cancer Drugs
Fiction writers and Hollywood love to paint a story of the cure for cancer being locked up in a vault in Switzerland by evil corporate henchmen. First, a cure would be patentable, and so it would be worth billions to whoever owned the patent. The idea that a for-profit firm would refuse to sell a profitable product is pure fiction. Cancer kills one out of five people, including Pharmaceutical CEOs and FDA Scientists. If there was a proven cure out there, we would all know about it.
Instead of a conspiracy to prevent a cure, what we have are a set of systems that work to prevent promising treatments from being tested. This is not intentional, but is the result of financial and regulatory decisions by business and government agencies. Take the FDA, for example. This agency is mostly staffed by smart, hard-working people making a lot less than their industry counterparts. They would love to see improved treatments, after all, their kids and their neighbor’s kids get leukemia, too.
Unfortunately, if you have a brand-new therapy for cancer, FDA makes you try it on the sickest patients, who have already failed previous, approved treatments. We know from animal tests that if we could intervene earlier in the disease process, we would get better outcomes. Testing a new treatment on the sickest patients is like pouring a new brand of racing fuel in a 1975 Chevy Vega and expecting it to win the Indy 500.
Another myth is the Company Research Department. While there are many excellent researchers in private firms, these are businesses with an obligation to make money for their shareholders. There is nothing wrong with this setup, but there are two main problems at work here, First, there are lots of dead ends in drug discovery, to the smart companies have learned to feed higher off the food chain. This involves letting academics do the bulk of the tedious screening process, (with Federal Grant Money), then, they can cherry-pick the most promising treatments, fund the remaining research steps, and patent the drug. Another way is to take an already-approved drug and modify it to either extend the patent or make a new patent on it entirely. There is a joke around the Bay Area about a BioTech giant that they “hire more lawyers than doctors”.
So, now you have a new therapy with real potential, but it doesn’t fit the business model gold standard of a pill or liquid. Remember that single-action pills work well for simple diseases by fixing one machine in the factory, but we’re trying to fix the whole factory. So, if your new drug is a pill, it fits the companies’ business model (hooray!), but its simple action means that it’s usually a matter of time before the cancer cells mutate and are no longer vulnerable to the drug. It’s like hitting mosquitoes with DDT, the first time, you kill 99.99%, but the few resistant ones multiply, and pass on their genes, and now the whole population is resistant. This is why cancer drugs often work well for a few months, than lose their effectiveness.
You probably think an effective drug is one that will cure a majority of patients who take it. However, to a drug company, an effective cancer drug is one that works well enough to get FDA approval, and can be sold for a high profit margin. That’s why you see drugs that cost $10,000/month which add a few months of average survival to the patients who take them. There is nothing evil in this system, it’s just business. Pharmaceutical companies know how difficult it is to cure cancer, so they figure a poor, but profitable, solution is better than no solution at all.
Instead of a conspiracy to prevent a cure, what we have are a set of systems that work to prevent promising treatments from being tested. This is not intentional, but is the result of financial and regulatory decisions by business and government agencies. Take the FDA, for example. This agency is mostly staffed by smart, hard-working people making a lot less than their industry counterparts. They would love to see improved treatments, after all, their kids and their neighbor’s kids get leukemia, too.
Unfortunately, if you have a brand-new therapy for cancer, FDA makes you try it on the sickest patients, who have already failed previous, approved treatments. We know from animal tests that if we could intervene earlier in the disease process, we would get better outcomes. Testing a new treatment on the sickest patients is like pouring a new brand of racing fuel in a 1975 Chevy Vega and expecting it to win the Indy 500.
Another myth is the Company Research Department. While there are many excellent researchers in private firms, these are businesses with an obligation to make money for their shareholders. There is nothing wrong with this setup, but there are two main problems at work here, First, there are lots of dead ends in drug discovery, to the smart companies have learned to feed higher off the food chain. This involves letting academics do the bulk of the tedious screening process, (with Federal Grant Money), then, they can cherry-pick the most promising treatments, fund the remaining research steps, and patent the drug. Another way is to take an already-approved drug and modify it to either extend the patent or make a new patent on it entirely. There is a joke around the Bay Area about a BioTech giant that they “hire more lawyers than doctors”.
So, now you have a new therapy with real potential, but it doesn’t fit the business model gold standard of a pill or liquid. Remember that single-action pills work well for simple diseases by fixing one machine in the factory, but we’re trying to fix the whole factory. So, if your new drug is a pill, it fits the companies’ business model (hooray!), but its simple action means that it’s usually a matter of time before the cancer cells mutate and are no longer vulnerable to the drug. It’s like hitting mosquitoes with DDT, the first time, you kill 99.99%, but the few resistant ones multiply, and pass on their genes, and now the whole population is resistant. This is why cancer drugs often work well for a few months, than lose their effectiveness.
You probably think an effective drug is one that will cure a majority of patients who take it. However, to a drug company, an effective cancer drug is one that works well enough to get FDA approval, and can be sold for a high profit margin. That’s why you see drugs that cost $10,000/month which add a few months of average survival to the patients who take them. There is nothing evil in this system, it’s just business. Pharmaceutical companies know how difficult it is to cure cancer, so they figure a poor, but profitable, solution is better than no solution at all.
Subscribe to:
Comments (Atom)
